HomeClinical TopicsFDA expands use of Gilenya to pediatric patients with MS

FDA expands use of Gilenya to pediatric patients with MS

Author(s):

On May 11, the U.S. Food and Drug Administration (FDA) approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first drug FDA has approved for treating MS in pediatric patients.

Read more via FDA.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

NP taking pregnant woman's blood pressure

AHA: It’s Safe to Treat High Blood Pressure During Pregnancy

High blood pressure during pregnancy can present significant risks to mother and child, but practitioners have sometimes be hesitant to prescribe blood pressure medication...